Combination bacteriolytic therapy for the treatment of tumors

Details Combination bacteriolytic therapy for the treatment of tumors Combination bacteriolytic therapy for the treatment of tumors

2011-08-30

2011-08-30

Ware, Debbie K (Department: 1651)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Bacteria or actinomycetales

C424S780000, C435S242000, C435S252700, C435S842000

Reexamination Certificate

active

08007782

ABSTRACT:
Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.

REFERENCES:
patent: 5554638 (1996-09-01), Dewhirst et al.
patent: 5688517 (1997-11-01), Helson et al.
patent: 7344710 (2008-03-01), Dang et al.
patent: 2003/0103987 (2003-06-01), Von Eichel-Streiber et al.
patent: WO 03/045131 (2003-06-01), None
patent: WO 2005/039491 (2005-05-01), None
Dang, Long H. et al, “Combination bacteriolytic therapy for the treatment of exper. tumors,” PNAS, p. 1-6, Oct. 2001.
D. Long et al., “Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors,” Proceedings of the National Academy of Sciences of USA, Dec. 18, 2001; vol. 98, No. 26, pp. 15155-15160.
J. Theys et al., “Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas,” FEMS Immunology and Medical Microbiology, Feb. 1, 2001, vol. 30, No. 1, pp. 37-41.
N.P. Minton et al., “Clostridia in Cancer Therapy,” Clostridia Biotechnology and Medical Applications, Feb. 15, 2001, pp. 251-270.
T. Fojo et al., “Taxol and Other Microtubule-Interactive Agents,” Current Opinion in Oncologic, Endocrine and Metabolicinvestigational Drugs, Jan. 1, 2001, vol. 2, No. 3, pp. 293-304.
R. F. Service, “Chemical Synthesis: Tumor-Killer Made: How Does it Work?” Science, Dec. 20, 1996, vol. 274, No. 5295, pp. 2009.
F. Valeriote et al., “Synergistic Interaction of Anticancer Agents: A Cellular Perspective,” Cancer Chemotherapy Reports, Sep. 1, 1975, vol. 59, No. 5, pp. 895-900.
D. Long et al., “Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents,” Cancer Biology & Therapy, Mar. 2004, vol. 3, No. 3, pp. 326-337.

Affiliated with

Also associated with

Rating

Combination bacteriolytic therapy for the treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination bacteriolytic therapy for the treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination bacteriolytic therapy for the treatment of tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2779476